Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 234 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism and Excretion Clear all

Conditions: Healthy
Interventions: [14C]MK-8527; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity, Cardiovascular Disease
Interventions: Alpha-cyclodextrin and digestible starch, Alpha-cyclodextrin, Digestible starch; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Healthy Volunteer
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: JNJ-42756493; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: varespladib methyl; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Osteoporosis
Interventions: SB-751689; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Adult Male
Interventions: [14C]-VVZ-149; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: [14C] MK-5475; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-TNP-2092; Drug
Lead sponsor: TenNor Therapeutics Limited; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: GDC-0032; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: OIC
Interventions: TD-1211 IV [C14], TD-1211 PO [C14]; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: 14C-labeled ASP0367; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Emraclidine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: Fenebrutinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Quemliclustat; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: [14C]-darigabat; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Hematologic Malignancies
Interventions: DSP-5336, [14C]-DSP-5336; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Pain
Interventions: 14C-VX-993; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Secondary Hypogonadism
Interventions: Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 19 Years to 60 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: RDEA3170 10 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

TD-1211 IV/Oral Mass Balance Study

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Mass Balance Study of KBP-5074 in Healthy Male Subjects

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

RDEA3170 AME Study